丹麦 - 丹麦文 - Lægemiddelstyrelsen (Danish Medicines Agency)

teva b.v. - ipratropiumbromid, salbutamolsulfat - inhalationsvæske til nebulisator, opløsning, enkeltdosisbeholder - 2,5+0,5 mg/behold.

丹麦 - 丹麦文 - Lægemiddelstyrelsen (Danish Medicines Agency)

teva b.v. - ipratropiumbromidmonohydrat - inhalationsvæske til nebulisator, opløsning, enkeltdosisbeholder - 0,5 mg/2ml

丹麦 - 丹麦文 - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm healthcare a/s - ipratropiumbromid, xylometazolinhydrochlorid - næsespray, opløsning - 0,6 mg/ml+0,5 mg/ml

丹麦 - 丹麦文 - Lægemiddelstyrelsen (Danish Medicines Agency)

opella healthcare france sas - ipratropiumbromid - næsespray, opløsning - 21 mikrogram/dosis

丹麦 - 丹麦文 - Lægemiddelstyrelsen (Danish Medicines Agency)

nordic prime aps - ipratropiumbromid - næsespray, opløsning - 21 mikrogram/dosis

欧盟 - 丹麦文 - EMA (European Medicines Agency)

novartis europharm limited - indacaterol, glycopyrronium bromid - pulmonal sygdom, kronisk obstruktiv - adrenergica i kombinationer med antikolinergika inkl. tredobbelte kombination med kortikosteroider - xoterna breezhaler er indiceret som bronkodilaterende vedligeholdelsesbehandling at lindre symptomer hos voksne patienter med kronisk obstruktiv lungesygdom (kol).

欧盟 - 丹麦文 - EMA (European Medicines Agency)

novartis europharm limited - indacaterol, glycopyrronium bromid - pulmonal sygdom, kronisk obstruktiv - adrenergica i kombinationer med antikolinergika inkl. tredobbelte kombination med kortikosteroider, medicin til obstruktiv sygdomme, - ultibro breezhaler er indiceret som bronkodilaterende vedligeholdelsesbehandling at lindre symptomer hos voksne patienter med kronisk obstruktiv lungesygdom (kol).

欧盟 - 丹麦文 - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a. - beclometasone dipropionate, formoterol fumarate dihydrat, glycopyrronium bromid - pulmonal sygdom, kronisk obstruktiv - medicin for obstruktiv sygdomme, - maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year. copdmaintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or a combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5. asthmamaintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.

欧盟 - 丹麦文 - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a. - beclometasone dipropionate, formoterol fumarate dihydrat, glycopyrronium - pulmonal sygdom, kronisk obstruktiv - medicin for obstruktiv sygdomme, - vedligeholdelsesbehandling hos voksne patienter med moderat til svær kronisk obstruktiv lungesygdom (kol), der ikke er tilstrækkeligt behandlet ved en kombination af et inhaleret binyrebarkhormon og en langtidsvirkende beta2-agonist (for effekter på symptomer kontrol og forebyggelse af eksacerbationer se afsnit 5.

欧盟 - 丹麦文 - EMA (European Medicines Agency)

novartis europharm limited - indacaterol, glycopyrronium bromide, mometasone - astma - medicin for obstruktiv sygdomme, - enerzair breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.